CoChat

Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands

Open access
Franken, Margreet G., Kanters, Tim A., Coenen, Jules L., de Jong, Paul, Koene, Harry R., Lugtenburg, Pieternella J., Jager, Agnes, Uyl-de Groot, Carin A. · 2018 · Anti-Cancer Drugs

The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.

Abstract

There is little evidence on the costs associated with the route of administration of oncology drugs. We investigated time and resource use for hospitals and patients and compared healthcare and societal costs for intravenous (IV) and subcutaneous (SC) administration of trastuzumab and rituximab. Data for the preparation and administration of both drugs were collected at the hospital pharmacy and at the oncology day care unit. Patients completed a questionnaire for obtaining information on societal costs (productivity losses, informal care and traveling expenses). A total of 126 patients were recruited in six hospitals; 82 received trastuzumab (37 IV and 45 SC) and 44 received rituximab (23 IV and 21 SC). The costs per administration (including societal cost but excluding drug costs) were &OV0556;167 and &OV0556;264 for IV and &OV0556;76 and &OV0556;146 for SC trastuzumab and rituximab, respectively. The costs for SC administration were lower in all categories. The largest cost component was related to time spent at the day care unit (overhead costs). This resulted in savings of &OV0556;47 for SC trastuzumab and &OV0556;69 for SC rituximab. The costs related to time of healthcare professionals was &OV0556;9 lower for both drugs. The costs for consumables resulted in another &OV0556;12 savings. Societal costs were &OV0556;22 lower for SC trastuzumab and &OV0556;28 lower for SC rituximab. Although administration costs are relatively a small part of the total costs, important savings can be generated by switching to an SC route of administration especially because a large number of patients receive oncology drugs and patients receive more than one administration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/cad.0000000000000648

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 1

  1. Ponzetti, 2016, Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 italian hospitals based on a systematic survey, Clinicoecon Outcomes Res, 8, 227

Cited by

See all 37

Metadata

Authors
Franken, M. G., Kanters, T. A., Coenen, J. L., de Jong, P., Koene, H. R., Lugtenburg, P. J., Jager, A., & Uyl-de Groot, C. A.
Affiliations
  • Erasmus University Rotterdam (NL)
  • Isala (NL)
  • St. Antonius Ziekenhuis (NL)
  • Erasmus MC Cancer Institute (NL)
Corresponding author
Franken, Margreet G.
Venue
Anti-Cancer Drugs
Published
2018-09
Volume
29
Issue
8
Pages
791-801
ISSN
0959-4973 (ISSN-L)
OpenAlex
W2805001001
Cited by
37
References
21
Citations by year
2026: 2 · 2025: 7 · 2024: 6 · 2023: 2 · 2022: 8 · 2021: 6 · 2020: 3 · 2019: 3
FWCI
4.55
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Anti-Cancer Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Funders
  • Roche Nederland
  • Erasmus Medisch Centrum
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Safe Handling of Antineoplastic Drugs
Keywords
route of administration, subcutaneous administration, intravenous administration, trastuzumab, rituximab, oncology drugs, health care costs, social costs, productivity loss, informal care, hospital pharmacy, cost reduction
MeSH terms
Trastuzumab, Rituximab, Antineoplastic Agents, Immunological, Aged, Female, Humans, Infusions, Intravenous, Injections, Subcutaneous, Male, Middle Aged, Netherlands, Retrospective Studies, Drug Costs, Infusions, Subcutaneous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. https://app.cochat.ai/papers/10.1097/cad.0000000000000648
The paper
Franken, M. G., Kanters, T. A., Coenen, J. L., de Jong, P., Koene, H. R., Lugtenburg, P. J., Jager, A., & Uyl-de Groot, C. A. (2018). Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anti-Cancer Drugs. https://doi.org/10.1097/cad.0000000000000648

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.